China
Africa
Explore chapters and articles related to this topic
Nausea/Vomiting of Pregnancy and Hyperemesis Gravidarum
Published in Vincenzo Berghella, Maternal-Fetal Evidence Based Guidelines, 2022
Cimetidine, famotidine, ranitidine, and nizatidine are approved for use in pregnancy to treat symptoms of heartburn, acid reflux, and H. pylori, which can exacerbate n/v. They may be added if symptoms are present. No RCTs exist regarding their effectiveness for NVP or HG. A meta-analysis showed no increased risk of congenital malformations, risk of spontaneous abortions, or preterm delivery compared to controls [78]. In intractable cases of n/v with positive H. pylori serology, a non-randomized study suggested benefit with triple therapy of ranitidine/flagyl/ampicillin [79].
F
Published in Caroline Ashley, Aileen Dunleavy, John Cunningham, The Renal Drug Handbook, 2018
Caroline Ashley, Aileen Dunleavy, John Cunningham
Metabolism of famotidine occurs in the liver, with formation of an inactive metabolite, the sulfoxide. Following oral administration, the mean urinary excretion of famotidine is 65–70% of the absorbed dose, 25–30% as unchanged compound. Renal clearance is 250–450 mL/min, indicating some tubular excretion. A small amount may be excreted as the sulfoxide.
Information on level of drugs into breastmilk
Published in Wendy Jones, Breastfeeding and Medication, 2018
Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JD, Baier J, Scheimann AO, Panebianco DL, Zhong L, Eisenhandler R, Yeh KC, Kearns GL, Pharmacokinetics of famotidine in infants, Clin Pharmacokinet, 2005;44:395–406.
Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
Published in Drug Delivery, 2023
Nabil A. Shoman, Marwa Saady, Mahmoud Teaima, Rehab Abdelmonem, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal
The efficacy and safety profile of ETO plus the frequent use of analgesics that may cause severe GIT disturbances and ulcers have contributed to the evolution of this research work. Methods to reduce the drug’s GIT side effects like the incorporation of antacids (H2 blockers) (Birk & Myers, 2009), and designing the floating raft systems (RS) (in-situ gelling approach) were proposed. Clinical evidence has proven that famotidine in combination with NSAIDs can be used to minimize the GIT side effects resulting from the frequent use of analgesics (Birk & Myers, 2009; Bello, 2012; Deeks, 2013; Sugano, 2013; Bello et al., 2015; Taha, 2015). Famotidine is a selective H2 receptor antagonist that is used to treat GIT ulcers by inhibiting both the concentration and volume of gastric acid secretions (Bello, 2012).
Renally inappropriate medications in elderly outpatients and inpatients with an impaired renal function
Published in Hospital Practice, 2023
Shotaro Kobayashi, Norio Sugama, Hiroyuki Nagano, Masahiro Takahashi, Akifumi Kushiyama
In the present study, each institution included outpatients, inpatients, and visiting facilities. The predominant RIMs in outpatient were allopurinol, famotidine, and loxoprofen. These drugs were also reported in previous documents [21–25]. Allopurinol is used in more than 100 countries around the world and is widely used as a treatment for gout. Famotidine and loxoprofen are also frequently used and can be purchased at pharmacies as over-the-counter medications. As RIMs in inpatient settings, some diabetic drugs and cardiovascular drugs, such as glimepiride and spironolactone, are significantly more frequently prescribed than in outpatients. These drugs may increase the risk of ADRs, such as hypoglycemia and hyperkalemia, when the renal function declines [19,26]. However, these drugs may still be safely used with frequent blood tests and side-effect monitoring. It should be kept in mind that the renal function decreases with age [10,27]; as such, even if drugs are not inappropriate at the time of prescription, they may become inappropriate with long-term use.
Soluplus® based solid dispersion as fast disintegrating tablets: a combined experimental approach for enhancing the dissolution and antiulcer efficacy of famotidine
Published in Drug Development and Industrial Pharmacy, 2020
Mona Basha, Abeer Salama, Shereen H. Noshi
The aim of the present work was to address a convenient antiulcerogenic dosage form for geriatric patients containing famotidine, which is considered one of the widely prescribed medications for treatment of peptic ulcer. Solid dispersions using SP as solubilizer were developed as an attempt to enhance the poor aqueous solubility of FM and the one composed of FM: SP (1:10) using freeze-drying technique (FM-SP10), showed the highest saturation solubility. Accordingly, fast disintegrating tablets incorporating FM-SP10 were prepared by direct compression employing three commercially available excipients; FM-melt, PF, and FU. As observed, FU based tablets (FM-FDT-FU) exhibited the shortest disintegration time and highest dissolution profile and were evaluated for their therapeutic efficacy using ethanol induced gastric ulcer model in rats. The results revealed the gastroprotective activity of the tested tablets showing normal gastric tissue with no edema or leucocytes infiltration. The obtained healing efficacy is likely due to the antioxidant and anti-inflammatory effect of FM-FDT-FU confirmed by the biochemical marker analysis. Thus, the development of FDT of FM solid dispersions could be used as a promising combined approach with prominent gastroprotective activity for management of peptic ulcer.